Events November 19-20, 2020 2020 Drugging Autophagy Summit Genoscience Pharma has presented at The Drugging Autophagy Summit its Phase 1b results, where all…Read More
News Nov. 18, 2020 GNS561’s successful phase 1b trial completed Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary…Read More
News July 22, 2020 GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition Marseille, July 22, 2020_ Therapeutic Advances in Chronic disease just published Genoscience Pharma's article E…Read More
News 18 June, 2020 Our COVID-19 research Project supported by the French Government Marseille, June 18, 2020_ The French Government announced in today's press release that Genoscience Pharma…Read More
Events June 22-24, 2020 AACR 2020 Virtual Annual Meeting GENOSCIENCE PHARMA Announces Remarkable Data on GNS561 in Combination with anti-PD1 to be Presented at…Read More
News April 6, 2020 COVID-19, GNS561’s Assault begins in France ! Marseille, April 6, 2020 — Genoscience Pharma Starts a phase 2 multicenter study using GNS561,…Read More
News January 13, 2020 ISO9001:2015 Certification for our R&D and Clinical Activities in Oncology Marseille, January 13, 2020 - Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and…Read More
Events January 13-15, 2020 Biotech Showcase™ 2020 Biotech Showcase™ 2020 - San Francisco, California Investor conference We will be present during…Read More
News December 16, 2019 GNS561 to treat pancreas or colorectal cancer with liver metastasis GENOSCIENCE PHARMA Announces Extension of GNS561 Phase 1/2 Clinical Trial to Patients with Pancreas or…Read More
Events December 2, 2019 The GoforIsrael Investment Conference 2019 The GoforIsrael - Investment Conference 2019 - Tel Aviv, Israel We are honored to…Read More